# A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

> **NCT00362466** · PHASE3 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 3 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00362466
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Insufficient Enrollment
- **Last updated:** 2009-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362466, "A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00362466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*